Interventions

background

Investigational

Therapeutic

  • Anti-inflammatory medications mainly used to treat ulcerative colitis
  • Only appropriate in general for septic complications, bacterial overgrowth, post-operative prophylaxis or perianal disease
  • Anti-TNF are indicated for moderate and severe IBD
  • Vedolizumab has been shown to be effective and safe for patients suffering from moderate-to-severe Crohn’s disease or UC
  • Corticosteroid that has low systemic bioavailability and is effective for inducing remission in mild ileal and ileocaecal Crohn’s disease
  • T-cell inhibiting calcineurin inhibitors are of limited value in Crohn’s disease and are mainly used in acute severe UC
  • Potent anti-inflammatory agents, primarily used for moderate to severe relapses of Crohn’s disease
  • Generally reserved for those refractory or intolerant to thiopurines or anti-TNF
  • AZA & 6-MP are used to avoid prolonged steroid use by maintaining remission
  • Overview of surgical procedures, including for jejunal and ileal disease, colonic disease and perianal disease
  • Includes enteral polymeric feeds, parenteral nutrition & other nutritional therapy

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.